Tests KarXT with KarX-EC for agitation in Alzheimer's disease
Tests KarXT with KarX-EC against placebo in adults with Alzheimer's-related agitation.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Deagu, Incheon, and Seoul, South KoreaSee the 10 sitesAlso in 13 other countries, 127 sites
- Trial code
- NCT07011745
- EU 2025-520612-34-00
- U1111-1316-5827
- Registry title
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 426 people, planned
- Started
- 16 Jul 2025
- Expected to end
- 13 Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Xanomeline/Trospium Chloride Capsule
- Xanomeline Enteric Capsule
- Placebo
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 90 with Alzheimer's disease who also have agitation (restless, aggressive behaviour). A caregiver must be able to help with the study.
- Age
- 55 Years to 90 Years
- Sex
- All sexes can join.
- Disease stage
- Alzheimer's disease confirmed by tests. MMSE score of 24 or lower at Screening. Agitation that began at least two weeks before Screening, with NPI/NPI-NH Agitation/Aggression score of 4 or more and CMAI-IPA Total Score of 30 or more.
- Earlier treatment
- Recent use of monoamine oxidase inhibitors, anticonvulsants, mood stabilizers, tricyclic antidepressants or other psychoactive medicines is not allowed. As-needed anxiolytics such as lorazepam are allowed. Some SSRIs and SNRIs taken at a stable dose for at least 8 weeks are allowed. Trazodone started at least 8 weeks before Screening may be used.
- Biomarker or test result
- Alzheimer's confirmed by amyloid PET, a spinal fluid (CSF) test, or a blood plasma test, using an authorized test.
Main reasons for not taking part
- Agitation mainly caused by something other than Alzheimer's disease
- History of bipolar disorder, schizophrenia or schizoaffective disorder
- History of, or high risk for, urinary retention, gastric retention or narrow-angle glaucoma
- Risk of suicidal behaviour during the study
- No caregiver with enough contact (about 8 hours a week) who is willing to take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:
- Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay
- If no historical evidence available:
- A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval
- If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:
- Amyloid PET
- Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay; Mini-Mental State Examination (MMSE) score of ≤ 24 at Screening (Visit 1); Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:; Attend all visits and report on participant's status
- Oversee participant compliance with medication and study procedures
- Participate in the study assessments and provide informed consent to participate in the study
- History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1)
- AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)
- Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score ≥ 30 at Screening (Visit 1) and Visit 2
Who cannot take part
- Prior/Concomitant Therapy
- Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam)
- Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted
- Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1); Note: Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1)
- Medical Conditions
- Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia
- History of bipolar disorder, schizophrenia, or schizoaffective disorder
- History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator
- Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR
- Other protocol-defined Inclusion/Exclusion criteria apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
- Has a doctor told you that you have Alzheimer's disease?
- Do you have agitation caused by Alzheimer's disease, such as being restless or aggressive?
- Do you have a caregiver or trial partner who sees you regularly and can help with the study?
- Has a doctor ever told you that you have bipolar disorder, schizophrenia or schizoaffective disorder?
Where in South Korea
Also in 13 other countries, 127 sites
- Kyungpook National University Chilgok HospitalDeagu, South KoreaContact: Ho-Won Lee, Site 2400Taking people
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Kee Hyung Park, Site 2409Taking people
- Inha University HospitalIncheon, South KoreaContact: Seong Hye Choi, Site 2401Taking people
- Asan Medical CenterSeoul, South KoreaContact: Jae-Sung Lim, Site 2402Taking people
- Gangnam Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Hanna Cho, Site 2408Taking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Seol-Heui Han, Site 2403Taking people
- Seoul National University HospitalSeoul, South KoreaContact: Manho Kim, Site 2407Taking people
- SMG-SNU Borame Medical CenterSeoul, South KoreaContact: Jun-Young Lee, Site 2405Taking people
- The Catholic University of Korea Yeouido St. Mary's HospitalSeoul, South KoreaContact: Hyun-Kook Lim, Site 2404Taking people
- Seoul, Seoul-teukbyeolsi [Seoul]Hospital not named in the registryNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
The 2 groups in the trial
- KarXT + KarX-ECTreatment being tested
Treatment: Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
- Plain-language title
- Tests KarXT with KarX-EC for agitation in Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07011745, who can take part
- Record updated
- 3 November 2026